HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
- 24 March 2022
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (12) , 1840-1846
Abstract
We previously demonstrated that pan-HDAC inhibitors could limit escape from MEK inhibitor (MEKi) therapy in uveal melanoma (UM) through suppression of AKT and YAP/TAZ signaling. Here, we focused on the role of specific HDACs in therapy adaptation. Class 2 UM displayed higher expression of HDACs 1, 2, and 3 than Class 1, whereas HDACs 6, 8, and 11 were uniformly expressed. Treatment of UM cells with MEKi led to modulation of multiple HDACs, with the strongest increases observed in HDAC11. RNA-seq analysis showed MEKi to decrease the expression of multiple HDAC11 target genes. Silencing of HDAC11 significantly reduced protein deacetylation, enhanced the apoptotic response to MEKi and reduced growth in long-term colony formation assays across multiple UM cell lines. Knockdown of HDAC11 led to decreased expression of TAZ in some UM cell lines, accompanied by decreased YAP/TAZ transcriptional activity and reduced expression of multiple YAP/TAZ target genes. Further studies showed this decrease in TAZ expression to be associated with increased LKB1 activation and modulation of glycolysis. In an in vivo model of uveal melanoma, silencing of HDAC11 limited the escape to MEKi therapy, an effect associated with reduced levels of Ki67 staining and increased cleaved caspase-3. We have demonstrated a novel role for adaptive HDAC11 activity in UM cells, that in some cases modulates YAP/TAZ signaling leading to MEKi escape.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R01 CA256193)
This publication has 39 references indexed in Scilit:
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse MechanismsClinical Cancer Research, 2012
- Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal MelanomaClinical Cancer Research, 2012
- Mutations inGNA11in Uveal MelanomaNew England Journal of Medicine, 2010
- An Accurate, Clinically Feasible Multi-Gene Expression Assay for Predicting Metastasis in Uveal MelanomaThe Journal of Molecular Diagnostics, 2010
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune toleranceNature Immunology, 2008
- Emerging Insights into the Molecular Pathogenesis of Uveal MelanomaFuture Oncology, 2008
- A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?International Journal of Cancer, 2003
- Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase FamilyJournal of Biological Chemistry, 2002